Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer
Summary. At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate. Aim: To evaluate the prognostic role of androgen receptor (AR) e...
Gespeichert in:
| Datum: | 2023 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
PH Akademperiodyka
2023
|
| Schlagworte: | |
| Online Zugang: | https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-9 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Experimental Oncology |
Institution
Experimental Oncology| id |
oai:ojs2.ex.aqua-time.com.ua:article-192 |
|---|---|
| record_format |
ojs |
| spelling |
oai:ojs2.ex.aqua-time.com.ua:article-1922023-10-11T16:43:03Z Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer Lyalkin, S.A. Verevkina, N.O. Alekseyenko, O.O. Syvak, L.A. androgen receptor, clinical prognosis, overall survival, triple negative breast cancer androgen receptor, clinical prognosis, overall survival, triple negative breast cancer Summary. At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate. Aim: To evaluate the prognostic role of androgen receptor (AR) expression in patients with TNBC. Materials and Methods: The effect of the AR expression level in tumor tissue on overall survival depending on clinical, histological and immunohistochemical characteristics of the tumor was evaluated in 116 patients with metastatic TNBC. Results: The independent prognostic value of AR expression in patients with TNBC of different stages was shown. The median overall survival was higher in patients with AR-positive tumors compared with AR-negative tumors (57 months vs 27 months, p < 0.0001). Five-year survival since diagnosis in the group with AR-positive TNBC was 47.6 ± 8.3% vs 20.0 ± 5.3% in the group with AR-negative TNBC (p < 0.05). Conclusions: The results of our study indicate a favorable impact of AR expression on the overall survival of TNBC patients. Summary. At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate. Aim: To evaluate the prognostic role of androgen receptor (AR) expression in patients with TNBC. Materials and Methods: The effect of the AR expression level in tumor tissue on overall survival depending on clinical, histological and immunohistochemical characteristics of the tumor was evaluated in 116 patients with metastatic TNBC. Results: The independent prognostic value of AR expression in patients with TNBC of different stages was shown. The median overall survival was higher in patients with AR-positive tumors compared with AR-negative tumors (57 months vs 27 months, p < 0.0001). Five-year survival since diagnosis in the group with AR-positive TNBC was 47.6 ± 8.3% vs 20.0 ± 5.3% in the group with AR-negative TNBC (p < 0.05). Conclusions: The results of our study indicate a favorable impact of AR expression on the overall survival of TNBC patients. PH Akademperiodyka 2023-06-01 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-9 10.32471/exp-oncology.2312-8852.vol-42-no-2.14579 Experimental Oncology; Vol. 42 No. 2 (2020): Experimental Oncology; 140-143 Експериментальна онкологія; Том 42 № 2 (2020): Експериментальна онкологія; 140-143 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-42-no-2 en https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-9/2020-2-9 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/ |
| institution |
Experimental Oncology |
| baseUrl_str |
|
| datestamp_date |
2023-10-11T16:43:03Z |
| collection |
OJS |
| language |
English |
| topic |
androgen receptor clinical prognosis overall survival triple negative breast cancer |
| spellingShingle |
androgen receptor clinical prognosis overall survival triple negative breast cancer Lyalkin, S.A. Verevkina, N.O. Alekseyenko, O.O. Syvak, L.A. Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| topic_facet |
androgen receptor clinical prognosis overall survival triple negative breast cancer androgen receptor clinical prognosis overall survival triple negative breast cancer |
| format |
Article |
| author |
Lyalkin, S.A. Verevkina, N.O. Alekseyenko, O.O. Syvak, L.A. |
| author_facet |
Lyalkin, S.A. Verevkina, N.O. Alekseyenko, O.O. Syvak, L.A. |
| author_sort |
Lyalkin, S.A. |
| title |
Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| title_short |
Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| title_full |
Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| title_fullStr |
Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| title_full_unstemmed |
Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| title_sort |
prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| title_alt |
Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer |
| description |
Summary. At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate. Aim: To evaluate the prognostic role of androgen receptor (AR) expression in patients with TNBC. Materials and Methods: The effect of the AR expression level in tumor tissue on overall survival depending on clinical, histological and immunohistochemical characteristics of the tumor was evaluated in 116 patients with metastatic TNBC. Results: The independent prognostic value of AR expression in patients with TNBC of different stages was shown. The median overall survival was higher in patients with AR-positive tumors compared with AR-negative tumors (57 months vs 27 months, p < 0.0001). Five-year survival since diagnosis in the group with AR-positive TNBC was 47.6 ± 8.3% vs 20.0 ± 5.3% in the group with AR-negative TNBC (p < 0.05). Conclusions: The results of our study indicate a favorable impact of AR expression on the overall survival of TNBC patients. |
| publisher |
PH Akademperiodyka |
| publishDate |
2023 |
| url |
https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-9 |
| work_keys_str_mv |
AT lyalkinsa prognosticroleofandrogenreceptorexpressioninpatientswithmetastatictriplenegativebreastcancer AT verevkinano prognosticroleofandrogenreceptorexpressioninpatientswithmetastatictriplenegativebreastcancer AT alekseyenkooo prognosticroleofandrogenreceptorexpressioninpatientswithmetastatictriplenegativebreastcancer AT syvakla prognosticroleofandrogenreceptorexpressioninpatientswithmetastatictriplenegativebreastcancer |
| first_indexed |
2025-07-17T12:16:22Z |
| last_indexed |
2025-07-17T12:16:22Z |
| _version_ |
1850411124936146944 |